KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cme (CME) EBITDA Margin (2016 - 2026)

Cme has reported EBITDA Margin over the past 18 years, most recently at 71.11% for Q1 2026.

  • Quarterly EBITDA Margin rose 198.0% to 71.11% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 66.76% through Mar 2026, up 50.0% year-over-year, with the annual reading at 64.86% for FY2025, 73.0% up from the prior year.
  • EBITDA Margin was 71.11% for Q1 2026 at Cme, up from 61.84% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 71.11% in Q1 2026 and troughed at 55.33% in Q4 2022.
  • The 5-year median for EBITDA Margin is 64.97% (2025), against an average of 64.63%.
  • Biggest five-year swings in EBITDA Margin: surged 543bps in 2022 and later tumbled -145bps in 2025.
  • Tracing CME's EBITDA Margin over 5 years: stood at 55.33% in 2022, then grew by 8bps to 59.97% in 2023, then increased by 4bps to 62.09% in 2024, then fell by 0bps to 61.84% in 2025, then grew by 15bps to 71.11% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 71.11%, 61.84%, and 64.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.